초록 ▼

A coating composition in the form of a one or multi-part system, and method of applying such a composition under conditions of controlled humidity, for use in coating device surfaces to control and/or improve their ability to release bioactive agents in aqueous systems. The coating composition is pa

A coating composition in the form of a one or multi-part system, and method of applying such a composition under conditions of controlled humidity, for use in coating device surfaces to control and/or improve their ability to release bioactive agents in aqueous systems. The coating composition is particularly adapted for use with medical devices that undergo significant flexion and/or expansion in the course of their delivery and/or use, such as stents and catheters. The composition includes the bioactive agent in combination with a first polymer component such as polyalkyl(meth)acrylate, polyaryl(meth)acrylate, polyaralkyl(meth)acrylate, or polyaryloxyalkyl(meth)acrylate and a second polymer component such as poly(ethylene-co-vinyl acetate).

대표청구항 ▼

What is claimed is: 1. A method for adjusting the rate of release of a bioactive agent from a coating composition provided in vivo, the method comprising the steps of: a) providing the coating composition comprising a bioactive agent in combination with a plurality of polymers, including a first po

What is claimed is: 1. A method for adjusting the rate of release of a bioactive agent from a coating composition provided in vivo, the method comprising the steps of: a) providing the coating composition comprising a bioactive agent in combination with a plurality of polymers, including a first polymer component selected from the group consisting of polyalkyl(meth)acrylates and aromatic poly(meth)acrylates, and a second polymer component comprising poly(ethylene-co-vinyl acetate), and b) altering a humidity level in which the coating composition is applied to a surface of a medical device to adjust the bioactive agent release profile, whereby increasing the humidity level accelerates the release of the bioactive agent and decreasing the humidity level decelerates the release of the bioactive agent. 2. A method according to claim 1 wherein the aromatic poly(meth)acrylates are selected from the group consisting of polyaryl(meth)acrylates, polyaralkyl(meth)acrylates, and polyaryloxyalkyl(meth)acrylates, and humidity is altered by a method selected from the group consisting of controlling the humidity at which the device is coated with the coating composition, controlling the water content of the coating composition, or combinations thereof. 3. A method according to claim 1 wherein the first polymer component is selected from the group consisting of: polyaryl(meth)acrylates, polyaralkyl(meth)acrylates, and polyaryloxyalkyl(meth)acrylates with aryl groups having from 6 to 16 carbon atoms, the first polymer component having a weight average molecular weight of about 50 to about 900 kilodaltons, and wherein the vinyl acetate content is between about 20% and about 40% by weight. 4. A method according to claim 1 wherein the bioactive agent is selected from the group consisting of thrombin inhibitors, antithrombogenic agents, thrombolytic agents, fibrinolytic agents, vasospasm inhibitors, calcium channel blockers, vasodilators, antihypertensive agents, antimicrobial agents, antibiotics, inhibitors of surface glycoprotein receptors, antiplatelet agents, antimitotics, microtubule inhibitors, anti secretory agents, actin inhibitors, remodeling inhibitors, antisense nucleotides, anti metabolites, antiproliferatives, anticancer chemotherapeutic agents, anti-inflammatory steroid or non-steroidal anti-inflammatory agents, immunosuppressive agents, growth hormone antagonists, growth factors, dopamine agonists, radiotherapeutic agents, peptides, proteins, enzymes, extracellular matrix components, ACE inhibitors, free radical scavengers, chelators, antioxidants, anti polymerases, antiviral agents, photodynamic therapy agents, and gene therapy agents. 5. A method according to claim 1, the concentration of bioactive agent being about 0.01 to about 90 percent, by weight, based on the weight of the coating composition. 6. A method according to claim 1, the coating composition thickness being about 0.1 micrometers to about 100 micrometers. 7. A method for adjusting the rate of release of a bioactive agent from a coating composition provided in vivo, the method comprising the steps of: a) providing the coating composition comprising a bioactive agent in combination with a plurality of polymers, including a first polymer component selected from the group consisting of polyalkyl(meth)acrylates and aromatic poly(meth)acrylates, and a second polymer component comprising poly(ethylene-co-vinyl acetate), and b) accelerating the release of the bioactive agent in vivo by increasing a humidity level in which the coating composition is applied to a surface of a medical device. 8. A method according to claim 7 wherein the aromatic poly(meth)acrylates are selected from the group consisting of polyaryl(meth)acrylates, polyaralkyl(meth)acrylates, and polyaryloxyalkyl(meth)acrylates, and humidity is altered by a method selected from the group consisting of controlling the humidity at which the device is coated with the coating composition, controlling the water content of the coating composition, or combinations thereof. 9. A method according to claim 7 wherein the first polymer component is selected from the group consisting of: polyaryl(meth)acrylates, polyaralkyl(meth)acrylates, and polyaryloxyalkyl(meth)acrylates with aryl groups having from 6 to 16 carbon atoms, the first polymer component having a weight average molecular weight of about 50 to about 900 kilodaltons, and wherein the vinyl acetate content is between about 20% and about 40% by weight. 10. A method according to claim 7 wherein the bioactive agent is selected from the group consisting of thrombin inhibitors, antithrombogenic agents, thrombolytic agents, fibrinolytic agents, vasospasm inhibitors, calcium channel blockers, vasodilators, antihypertensive agents, antimicrobial agents, antibiotics, inhibitors of surface glycoprotein receptors, antiplatelet agents, antimitotics, microtubule inhibitors, anti secretory agents, actin inhibitors, remodeling inhibitors, antisense nucleotides, anti metabolites, antiproliferatives, anticancer chemotherapeutic agents, anti-inflammatory steroid or non-steroidal anti-inflammatory agents, immunosuppressive agents, growth hormone antagonists, growth factors, dopamine agonists, radiotherapeutic agents, peptides, proteins, enzymes, extracellular matrix components, ACE inhibitors, free radical scavengers, chelators, antioxidants, anti polymerases, antiviral agents, photodynamic therapy agents, and gene therapy agents. 11. A method according to claim 7, the concentration of bioactive agent being about 0.01 to about 90 percent, by weight, based on the weight of the coating composition. 12. A method according to claim 7, the coating composition thickness being about 0.1 micrometers to about 100 micrometers. 13. A method for adjusting the rate of release of a bioactive agent from a coating composition provided in vivo, the method comprising the steps of: a) providing the coating composition comprising a bioactive agent in combination with a plurality of polymers, including a first polymer component selected from the group consisting of polyalkyl(meth)acrylates and aromatic poly(meth)acrylates, and a second polymer component comprising poly(ethylene-co-vinyl acetate), and b) decelerating the release of the bioactive agent in vivo by decreasing the humidity level in which the coating composition is applied to a surface of a medical device. 14. A method according to claim 13 wherein the aromatic poly(meth)acrylates are selected from the group consisting of polyaryl(meth)acrylates, polyaralkyl(meth)acrylates, and polyaryloxyalkyl(meth)acrylates, and humidity is altered by a method selected from the group consisting of controlling the humidity at which the device is coated with the coating composition, controlling the water content of the coating composition, or combinations thereof. 15. A method according to claim 13 wherein the first polymer component is selected from the group consisting of: polyaryl(meth)acrylates, polyaralkyl(meth)acrylates, and polyaryloxyalkyl(meth)acrylates with aryl groups having from 6 to 16 carbon atoms, the first polymer component having a weight average molecular weight of about 50 to about 900 kilodaltons, and wherein the vinyl acetate content is between about 20% and about 40% by weight. 16. A method according to claim 13 wherein the bioactive agent is selected from the group consisting of thrombin inhibitors, antithrombogenic agents, thrombolytic agents, fibrinolytic agents, vasospasm inhibitors, calcium channel blockers, vasodilators, antihypertensive agents, antimicrobial agents, antibiotics, inhibitors of surface glycoprotein receptors, antiplatelet agents, antimitotics, microtubule inhibitors, anti secretory agents, actin inhibitors, remodeling inhibitors, antisense nucleotides, anti metabolites, antiproliferatives, anticancer chemotherapeutic agents, anti-inflammatory steroid or non-steroidal anti-inflammatory agents, immunosuppressive agents, growth hormone antagonists, growth factors, dopamine agonists, radiotherapeutic agents, peptides, proteins, enzymes, extracellular matrix components, ACE inhibitors, free radical scavengers, chelators, antioxidants, anti polymerases, antiviral agents, photodynamic therapy agents, and gene therapy agents. 17. A method according to claim 13, the concentration of bioactive agent being about 0.01 to about 90 percent, by weight, based on the weight of the coating composition. 18. A method according to claim 13, the coating composition thickness being about 0.1 micrometers to about 100 micrometers.